Therapeutic Effect of Oncolytic Herpes Simplex Virus Type 1 (G47Δ) in Combination with Chemotherapy on Colorectal Cancer

被引：1
|
作者：
Abe, Shinya [1 ]
Ino, Yasushi [1 ]
Fukuhara, Hiroshi [2 ]
Iwai, Miwako [1 ]
Watanabe, Toshiaki [3 ]
Todo, Tomoki [1 ]
机构：
[1] Univ Tokyo, Inst Med Sci, Div Innovat Canc Therapy, Tokyo, Japan
[2] Univ Tokyo, Dept Urol, Tokyo, Japan
[3] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan
来源：
MOLECULAR THERAPY | 2016年 / 24卷
关键词：
D O I：
10.1016/S1525-0016(16)33472-4
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
664
引用
收藏
页码：S263 / S263
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of triple-mutated oncolytic herpes virus G47 increment in patients with progressive glioblastoma
    Todo, Tomoki
    Ino, Yasushi
    Ohtsu, Hiroshi
    Shibahara, Junji
    Tanaka, Minoru
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [42] Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?
    Kanai, Ryuichi
    Wakimoto, Hiroaki
    Cheema, Tooba
    Rabkin, Samuel D.
    FUTURE ONCOLOGY, 2010, 6 (04) : 619 - 634
  • [43] Enhanced efficacy of immune checkpoint inhibitors when used in combination with oncolytic HSV-1 G47Δ in lung cancer
    Sakata, Yoshinori
    Ino, Yasushi
    Iwai, Miwako
    Ikeda, Norihiko
    Todo, Tomoki
    CANCER SCIENCE, 2018, 109 : 917 - 917
  • [44] The Efficacy of Oncolytic HSV-1 (G47Δ) for Biliary Tract Cancer in Mouse Models
    Tateno, Yoko
    Ino, Yasushi
    Iwai, Miwako
    Shinozaki, Masaru
    Todo, Tomoki
    MOLECULAR THERAPY, 2018, 26 (05) : 347 - 348
  • [45] Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation
    Sugawara, Kotaro
    Iwai, Miwako
    Ito, Hirotaka
    Tanaka, Minoru
    Seto, Yasuyuki
    Todo, Tomoki
    MOLECULAR THERAPY-ONCOLYTICS, 2021, 22 : 129 - 142
  • [46] New generation, conditionally replicating herpes simplex virus G47Δ as a potential backbone vector for expressing foreign proteins
    Fukuhara, H
    Todo, T
    DRUGS OF THE FUTURE, 2003, 28 (01) : 43 - 49
  • [47] Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10
    Teshigahara, O
    Goshima, F
    Takao, K
    Kohno, S
    Kimata, H
    Nakao, A
    Nishiyama, Y
    JOURNAL OF SURGICAL ONCOLOGY, 2004, 85 (01) : 42 - 47
  • [48] Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
    Kooby, DA
    Carew, JF
    Halterman, MW
    Mack, JE
    Bertino, JR
    Blumgart, LH
    Federoff, HJ
    Fong, YM
    FASEB JOURNAL, 1999, 13 (11): : 1325 - 1334
  • [49] The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
    Uche, Ifeanyi Kingsley
    Kousoulas, Konstantin G.
    Rider, Paul J. F.
    VIRUSES-BASEL, 2021, 13 (07):
  • [50] Efficacy of Third-Generation Oncolytic Herpes Virus G47Δ Combined with Immune Checkpoint Inhibitors in Renal Cell Carcinoma Models
    Sasaki, Kenichi
    Takeshima, Yuta
    Iwai, Miwako
    Fukuhara, Hiroshi
    Kume, Haruki
    Todo, Tomoki
    MOLECULAR THERAPY, 2024, 32 (04) : 820 - 820
12345